Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5175940 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTMEN1USP2KMT2A | |
| SCHEMBL5055232 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTMEN1USP2KMT2A | |
| SCHEMBL5028645 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTMEN1USP2KMT2A | |
| Acrylamide SCHEMBL28120831 | 0.77 | ALDH1A1 (0.50) | ALDH1A1MAPTMEN1USP2KMT2A | |
| SCHEMBL9570820 | 0.76 | CNR2 (0.45) | ALDH1A1MAPTMEN1USP2KMT2A | |
| SCHEMBL9570817 | 0.76 | CNR2 (0.45) | ALDH1A1MAPTMEN1USP2KMT2A | |
| SCHEMBL4141434 | 0.74 | HPGD (0.43) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL11306763 | 0.74 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1USP2KMT2A | |
| SCHEMBL679130 | 0.74 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1USP2KMT2A | |
| SCHEMBL679131 | 0.74 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1USP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | ALDH1A1 3755/4885MAPT 3736/4885MEN1 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.